Mindset Pharma Inc (CSE:MSET, OTCQB:MSSTF, FRA:9DF). (CSE:MSET) (FSE:9DF) (OTCQB:MSSTF) CEO James Lanthier tells Proactive the Toronto, Canada-based psychedelics-focused drug discovery and development company has filed an international patent application for its psilocybin synthesis method.
Lanthier says the patent application covers Mindset’s synthesis process that enables faster psilocin and psilocybin synthesis, lower cost, milder reaction conditions, more convenient operations, easily obtained commercially available raw materials, suitability for multi-kilogram scale manufacturing, and lower environmental impact.